On June 6, Finnegan client Eli Lilly and Company filed suit in the District of New Jersey in a bid to keep India’s Hetero Drugs from producing a generic version of the blockbuster ADHD drug Strattera® for the U.S. market. The suit claims that Hetero's filing of the ANDA constituted an act of infringement and that “Lilly will be substantially and irreparably harmed by Hetero's infringing activities unless those activities are enjoined by this court.” Eli Lilly and Company is represented by Finnegan in this matter.
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
Behind the Case: How Finnegan Helped Eli Lilly Swerve a $176.5M Patent Headache
October 10, 2023
Award/Ranking
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Award/Ranking
September 18, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.